Does orbital exenteration still has a place in 2019?
[Does orbital exenteration still has a place in 2019?] J Fr Ophtalmol. 2019 Dec 09;: Authors: Martel A, Hamedani M, Lagier J, Bertolotto C, Gastaud L, Poissonnet G Abstract INTRODUCTION: Orbital exenteration is a radical anatomically and psychologically disfiguring procedure. It is mostly performed for management of orbital cancers or cancers with orbital involvement. The lack of benefit in terms of overall survival and the development of new molecular therapies (targeted therapies, immunotherapy) in recent years leads us to question its use. The goal of our review is to answer to the following question: is orbital exenteration a viable procedure in 2019? MATERIALS AND METHODS: A literature review was performed using the PUBMED and MEDLINE databases. The following terms were used then crossed with each other: "orbital exenteration", "exenterated socket", "overall survival", "life expectancy", "orbital reconstruction", "socket reconstruction". Oncology articles from the past 15 years were included and separated into those in the oculoplastic literature and those in the ENT literature. RESULTS: Nineteen articles were included in this review. Eyelid tumours represent the main etiology of orbital exenteration. Basal cell carcinoma is the most frequently incriminated tumor, while sebaceous carcinoma and conjunctival squamous cell carcinoma are the most frequently encountered in Asian seri...
PANCREATIC cancer symptoms are often non-specific and vague in the beginning. One of the first noticeable signs is associated with your stomach.
Publication date: Available online 20 September 2020Source: Biochimica et Biophysica Acta (BBA) - Reviews on CancerAuthor(s): Marjolein M.G. Kes, Jan Van den Bossche, Arjan W. Griffioen, Elisabeth J.M. Huijbers
Publication date: Available online 19 September 2020Source: Biochimica et Biophysica Acta (BBA) - Reviews on CancerAuthor(s): Hang-Ping Yao, Rachel Hudson, Ming-Hai Wang
Conclusion: Moderate quality evidence suggests that OMTh is effective for CNCP patients. There was a significant association between visceral OMTh and reduced pain severity and disability. More robust, high-quality randomized controlled trials with larger sample sizes are required to further explore the effectiveness of the OMTh in the management of CNCP. PMID: 32946545 [PubMed - as supplied by publisher]
Invasive breast cancer deriving from the milk duct and lobule that develops in the nipple is extremely rare, except in Paget ’s disease and skin cancer. This is the second reported case of the development of invasive cancer confined to the nipple after breast-conserving surgery. A 69-year-old woman visited our department due to redness, swelling, and bloody discharge of the right nipple in the last month. A needle biops y was suggestive of invasive ductal carcinoma; we performed a removal surgery of the right residual breast tissue and a second sentinel lymph node biopsy. She underwent these procedures 10 years previ...
(Wiley) New research suggests that Black women experience longer waits for treatment initiation than white women after a breast cancer diagnosis, and their duration of treatment is prolonged. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society (ACS).
Lymphedema: Clinical Summary of the ONS Guidelines™ for Cancer Treatment-Related Lymphedema. Clin J Oncol Nurs. 2020 Oct 01;24(5):566-570 Authors: Backler C, Beck M, Poage E Abstract Secondary (acquired) lymphedema is a chronic condition lacking a known cure that most commonly results from cancer treatment, particularly for breast, gynecologic, prostate, and head and neck cancers; lymphoma; and melanoma, and affects an estimated 1 in 1,000 Americans. Lymphedema is characterized by an accumulation of protein-rich lymphatic fluid in the affected part of the body. It can potentially affect function...
Conclusions In this study, RNA-Seq analysis detected only 46-49% of pathogenic variants identifiable by sequencing of tumor DNA. Mutations were more often missed by RNA-Seq when present at low frequency or when tested on FNA samples. All TERT mutations were missed by RNA-Seq. These data suggest that RNA-Seq does not detect a significant proportion of clinically relevant mutations and should be used with caution in clinical practice for detecting DNA mutations. PMID: 32948110 [PubMed - as supplied by publisher]